Benzinga Logo
My account
QQQ
–%
DIA
–%
SPY
–%
TLT
–%
GLD
–%
BTC/USD
–%
Contribute
Sign in
Benzinga Logo
My Stocks
Tools
Calendars
Earnings Calendar
IPO Calendar
Guidance Calendar
FDA Calendar
Dividend Calendar
Stock Split Calendar
Conference Call Calendar
Economic Calendar
Trade Ideas
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Range
- - -
Vol / Avg.
-/3.2M
Div / Yield
-
52 Wk
2.09 - 5.14
Mkt Cap
499.2M
Payout Ratio
-
Open
-
P/E
-
EPS
-0.51
Shares
174.5M
Outstanding
174.5M
Total Float
150.5M
Benzinga - Aug 20, 2021, 9:19AM
Benzinga - Aug 5, 2021, 8:13AM
Benzinga - Jul 14, 2021, 12:30PM
Benzinga - Jun 10, 2021, 12:43PM
Benzinga - Jun 4, 2021, 10:27AM
Benzinga - Jun 1, 2021, 8:58AM
Benzinga - Jun 1, 2021, 7:28AM
Benzinga - Jun 1, 2021, 6:01AM
Benzinga - May 10, 2021, 8:10AM
Benzinga - Apr 28, 2021, 5:20PM
Benzinga - Mar 30, 2021, 6:03AM
Benzinga - Mar 25, 2021, 8:05AM
Benzinga - Mar 24, 2021, 8:06AM
Benzinga - Mar 8, 2021, 9:31AM
Benzinga - Mar 8, 2021, 7:53AM
Benzinga - Mar 8, 2021, 6:21AM
load more
Sector: Health Care.Industry: Biotechnology
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Earnings

see more
Q3 2021Est.ActualSurprise
EPS
(EXPECTED)2021-11-04
REV
Q2 2021Est.ActualSurprise
EPS-0.320-0.510 -0.1900
REV52.880M52.913M33.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
AKBAAkebia Therapeutics-0.34%499.2M

Akebia Therapeutics Questions & Anwsers

Q

How do I buy Akebia Therapeutics (AKBA) stock?

A

You can purchase shares of Akebia Therapeutics (NASDAQ: AKBA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Akebia Therapeutics's (AKBA) competitors?

A

Other companies in Akebia Therapeutics’s space includes: Innate Pharma (NASDAQ:IPHA), KalVista Pharmaceuticals (NASDAQ:KALV), VistaGen Therapeutics (NASDAQ:VTGN), Viking Therapeutics (NASDAQ:VKTX) and Cue Biopharma (NASDAQ:CUE).

Q

What is the target price for Akebia Therapeutics (AKBA) stock?

A

The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by Cantor Fitzgerald on March 8, 2021. The analyst firm set a price target for 8.00 expecting AKBA to rise to within 12 months (a possible 179.72% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Akebia Therapeutics (AKBA)?

A

The stock price for Akebia Therapeutics (NASDAQ: AKBA) is $2.86 last updated Fri Sep 24 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does Akebia Therapeutics (AKBA) pay a dividend?

A

There are no upcoming dividends for Akebia Therapeutics.

Q

When is Akebia Therapeutics (NASDAQ:AKBA) reporting earnings?

A
Akebia Therapeutics’s Q3 earnings are confirmed for after-market on November 4, 2021.
Q

Is Akebia Therapeutics (AKBA) going to split?

A

There is no upcoming split for Akebia Therapeutics.

Q

What sector and industry does Akebia Therapeutics (AKBA) operate in?

A

Akebia Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.